Amy Burroughs nomeada CEO da Terns Pharmaceuticals após liderar a Cleave Pharmaceuticals. Amy Burroughs appointed as Terns Pharmaceuticals CEO after leading Cleave Pharmaceuticals.

A Terns Pharmaceuticals nomeou Amy Burroughs como sua nova CEO. Terns Pharmaceuticals has appointed Amy Burroughs as its new Chief Executive Officer. Burroughs, que trabalhou anteriormente na Cleave Pharmaceuticals e na Crinetics Pharmaceuticals, também fará parte do conselho de administração da Terns. Burroughs, who previously worked at Cleave Pharmaceuticals and Crinetics Pharmaceuticals, will also join Terns' board of directors. Ela atuou como CEO da Cleave Pharmaceuticals de abril de 2019 a outubro de 2023. She served as the CEO of Cleave Pharmaceuticals from April 2019 to October 2023. Esta nomeação segue as recentes conquistas da Terns no desenvolvimento de um portfólio de candidatos a produtos de pequenas moléculas para tratar doenças graves, como oncologia e obesidade. This appointment follows Terns' recent achievements in developing a portfolio of small-molecule product candidates to address serious diseases, such as oncology and obesity.